ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
LOW-DENSITY-LIPOPROTEIN STIMULATION OF MESANGIAL CELL FIBRONECTIN SYNTHESIS - ROLE OF PROTEIN-KINASE-C AND TRANSFORMING GROWTH-FACTOR-BETA
Author(s): STUDER RK, CRAVEN PA, DERUBERTIS FR
Source: JOURNAL OF LABORATORY AND CLINICAL MEDICINE    Volume: 125    Issue: 1    Pages: 86-95    Published: JAN 1995  
Times Cited: 33     References: 48     
Abstract: Low-density lipoprotein (LDL) cholesterol has been implicated in the pathogenesis of glomerulosclerosis in diabetes and other forms of glomerular injury. In the present study we evaluated the effect of LDL on fibronectin synthesis in cultured rat mesangial cells (MCs) and the roles of protein kinase C (PKC) and transforming growth factor-beta (TGF-beta) in mediating this LDL action. In MCs, 25 mu g to 100 mu g/ml LDL increased PKC activity within 15 minutes, as reflected by enhanced in situ phosphorylation of the 80 kd myristoylated alanine-rich C kinase substrate protein, a specific endogenous substrate of PKC in MC. The same concentrations of LDL subsequently (18 to 72 hours) enhanced fibronectin synthesis, as reflected by increased incorporation of labeled methionine into fibronectin. GF 109203X, a selective inhibitor of PKC, blocked increases in both PKC activity and fibronectin synthesis induced by LDL in MCs. Furthermore, prior downregulation of PKC to less than 1% of basal activity by exposure of MCs to 0.5 mu mol/L phorbol myristate acetate (PMA) also prevented LDL stimulation of fibronectin synthesis. The activation of PKC by LDL seen after 15 minutes of exposure was transient and was not observed after 4 or 48 hours of exposure of MCs to LDL. However, exposure to LDL for 48 hours, but not for 15 minutes or 4 hours, increased both maximal PKC responses to phorbol dibutyrate (PDBu) and tritiated PDBu binding to MCs by 30%. These findings suggest that chronic exposure to LDL increases the total PKC content in MCs and thereby might modulate responses to other PKC agonists. Neither the cyclooxygenase inhibitor piroxicam nor the thromboxane/prostaglandin endoperoxide receptor blocker Sq-29548 altered LDL stimulation of fibronectin synthesis in MCs, suggesting that this action of LDL was not mediated by changes in MC eicosanoid generation. By contrast, antibody to TGF-beta blocked LDL stimulation of fibronectin synthesis in MCs. TGF-beta bioactivity, determined with the mink lung epithelial cell assay, was two to three times higher in the medium of MCs cultured with LDL for 24 to 48 hours as compared with corresponding control values. Total TGF-beta bioactivity examined after heat activation of latent TCF-beta was also two times higher in the medium of MCs exposed to LDL as compared with that of controls. Prior down-regulation of PKC by exposure of MCs to PMA blocked the increases in TGF-beta bioactivity Induced by LDL. The results thus implicate both activation of PKC and TGF-beta in the expression of the action of LDL to enhance fibronectin synthesis in MCs. They suggest that activation of PKC by LDL signals increases in TGF-beta bioactivity, which in turn mediates the LDL action to increase fibronectin synthesis in MCs.
Document Type: Article
Language: English
Addresses:
1. VET AFFAIRS MED CTR, PITTSBURGH, PA 15240 USA
2. UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA USA
Publisher: MOSBY-YEAR BOOK INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
Subject Category: Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental
IDS Number: QF867
ISSN: 0022-2143
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo